An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease

Respirology

Volumn 17, Issue 3, 2012, Pages 493-498

  Bando, Masashi ^a   Miyazawa, Tadashi ^a   Shinohara, Hideki ^b   Owada, Toshio ^b   Terakado, Michiyuki ^b   Sugiyama, Yukihiko ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Shimotsuke COPD Research Group   (Japan)

Author keywords

airflow limitation; chronic obstructive pulmonary disease; cross sectional study; statin use

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEALTH CARE FACILITY; HEALTH SERVICE; HEALTH STATUS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY AIRFLOW; RISK FACTOR; SMOKING; SPIROMETRY;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SEX FACTORS; SMOKING; SPIROMETRY;

EID: 84859014001     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02116.x     Document Type: Article

References (26)

1. Rabe KF, Hurd S, Anzueto A, et al,. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-5.
2. Sin DD, Man PSF,. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-19.
3. Gan WQ, Man SFP, Senthilselvan A, et al,. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-80.
4. Bhowmic A, Seemungal TA, Sapsford RJ, et al,. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-20.
5. Spruit MA, Gosselink R, Troosters T, et al,. Muscle force during an acute exacerbation in hospitalized patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58: 752-6.
6. Young RP, Hopkins R, Eaton TE,. Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 2009; 18: 222-32.
7. Fabbri LM, Rabe KF,. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797-9.
8. Barnes PJ, Celli BR,. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165-85.
9. Barnes PJ,. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med. 2010; 7: e1000220.
10. Schonbeck U, Libby P,. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as anti-inflammatory agents? Circulation 2004; 109: 118-26.
11. Rosenson RS, Tangney CC, Casey LC,. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983-4.
12. Albert MA, Danielson E, Rifai N, et al,. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
13. Blamoun AI, Batty GN, Debari VA, et al,. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int. J. Clin. Pract. 2008; 62: 1373-8.
14. Frost FJ, Petersen H, Tollestrup K, et al,. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131: 1006-12.
15. Ishida W, Kajiwara T, Ishii M, et al,. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J. Exp. Med. 2007; 212: 265-73.
16. Soyseth V, Brekke PH, Smith P, et al,. Statin use is associated with reduced mortality in COPD. Eur. Respir. J. 2007; 29: 279-83.
17. Walsh GM,. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2008; 2: 329-35.
18. Janda S, Park K, FitzGerald JM, et al,. Statins in COPD: a systematic review. Chest 2009; 136: 734-43.
19. Young RP, Hopkins R, Eaton TE,. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of evidence. Postgrad. Med. J. 2009; 85: 414-21.
20. Young RP, Hopkins R, Eaton TE,. Comorbidities in COPD. Eur. Respir. J. 2009; 34: 1497-500.
21. Fukuchi Y, Nishimura M, Ichinose M, et al,. COPD in Japan: the Nippon COPD epidemiology study. Respirology 2004; 9: 458-65.
22. Koga T, Tsuda T, Omori H, et al,. Epidemiological survey of unidentified COPD in medical check-up participants, primary care visitors and preoperative patients in the Kyushu area of Japan. Respir. Res. 2006; 25: 801-6.
23. Takahashi T, Ichinose M, Inoue H, et al,. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology 2003; 8: 504-8.
24. Geijer RM, Sachs AP, Hoes AW, et al,. Prevalence of undetected persistent airflow obstruction in male smokers 40-65 years old. Fam. Pract. 2005; 22: 485-9.
25. Keddissi JI, Younis WG, Chbeir EA, et al,. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-71.
26. Alexeeff SE, Litonjua AA, Sparrow D, et al,. Statin use reduces decline in lung function: VA Normative Aging Study. Am. J. Respir. Crit. Care Med. 2007; 176: 742-7.